George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

AstraZeneca completes buy of rare diseases specialist Alexion

Wed, 21st Jul 2021 16:48

(Alliance News) - AstraZeneca PLC on Wednesday sealed its acquisition of Alexion Pharmaceuticals Inc in a cash-and-stock deal worth about USD39 billion.

The coronavirus jab maker bought Alexion, a Boston, Massachusetts-based biotech firm specialising in rare diseases, for USD13.3 billion and 236,321,411 new AstraZeneca shares.

The confirmation comes after the UK Competition & Markets Authority cleared the Cambridge-based firm's takeover on July 14.

"Today we welcome our new colleagues from Alexion to AstraZeneca and begin a new chapter that will augment our growth for years to come," said Chief Executive Pascal Soriot.

"Our sustained R&D investment in oncology, cardiovascular and renal, as well as respiratory and immunology, has powered AstraZeneca's transformation and now we add rare diseases, where fewer approved treatment options exist."

Incoming CEO of Alexion and current AstraZeneca Chief Financial Officer Marc Dunoyer said he looks forward to extending "existing and future rare disease medicines" globally.

Over 7,000 rare diseases are known today and approximately 5% have treatments approved by the US Food and Drug Administration.

Shares in AstraZeneca closed marginally higher at 8,459.00 pence each in London on Wednesday.

By Josie O'Brien; josieobrien@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the...

27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downt...

27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the w...

27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation readin...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.